EGFR and lung cancer: Genetic alterations in MAPK/ERK pathway are very common in non‐small cell lung cancer (NSCLC), especially mutations found in the upstream members, EGFR and KRAS, which account for 70% or more of all known driver mutations (Ladanyi & Pao, 2008; Riely et al., 2008).